Pacific Biosciences of California (NASDAQ:PACB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, FiscalAI reports. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 81.31%. The business had revenue of $40.56 million during the quarter, compared to analyst estimates of $39.31 million.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• SPRQ-Nx adoption is expanding: it accounted for over half of Revio consumable revenue, and two-thirds of the install base had upgraded by quarter-end. PacBio expects adoption to broaden further and sees the lower cost per genome supporting higher utilization and stronger pull-through over time.
• Clinical genomics and strategic partnerships are gaining traction. Clinical consumables grew more than 20% year over year, while GeneDx plans to add long-read sequencing and Berry Genomics ordered 10 Revio systems for a five-year rare-disease program; PacBio also highlighted collaborations involving biomedical AI and drug discovery.
• Growth remains modest and uneven: Q3 revenue rose 6% year over year to $40.6 million, while consumables revenue fell year over year to $20.8 million as customers used existing inventory and validated new workflows. PacBio narrowed full-year revenue guidance to $155 million–$160 million and cited ongoing academic and government funding constraints.
• Gross margin declined to 36% from 42% a year earlier, with higher memory costs and Vega manufacturing transition costs weighing on results. The company ended the quarter with $199.4 million in cash, and management acknowledged that strategic deals will take time to translate into meaningful revenue and cash generation.
• PacBio said its high-throughput platform remains on track for commercial launch by the end of 2027, with development fully resourced. It continues to target cash-flow breakeven in 2028, citing planned expense reductions, although that goal depends on executing its product roadmap and growing revenue.

Pacific Biosciences of California Stock Performance

Shares of PACB stock traded down $0.17 on Friday, reaching $2.26. 2,654,686 shares of the company’s stock traded hands, compared to its average volume of 8,314,959. The company has a market capitalization of $701.86 million, a P/E ratio of -5.39 and a beta of 2.21. Pacific Biosciences of California has a 12-month low of $1.07 and a 12-month high of $3.43. The business’s 50 day moving average price is $1.91 and its two-hundred day moving average price is $1.62.

Analyst Upgrades and Downgrades

PACB has been the topic of several recent analyst reports. Barclays boosted their price objective on Pacific Biosciences of California from $1.25 to $2.00 and gave the stock an “underweight” rating in a report on Thursday. UBS Group initiated coverage on shares of Pacific Biosciences of California in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday. Weiss Ratings upgraded shares of Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Finally, Wall Street Zen downgraded shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pacific Biosciences of California presently has a consensus rating of “Reduce” and a consensus target price of $2.09.

Insider Activity

In other Pacific Biosciences of California news, insider Mark Van Oene sold 26,911 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the sale, the insider directly owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of Pacific Biosciences of California stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. This trade represents a 37.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.

Key Stories Impacting Pacific Biosciences of California

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported Q3 revenue of $40.56 million, above the $39.31 million consensus estimate, and a per-share loss of $0.11 versus expectations of $0.13. Coverage also highlighted clinical adoption and AI partnerships as growth supports. Zacks Q3 results article Q3 adoption and partnerships article
• Neutral Sentiment: Piper Sandler reaffirmed its neutral rating while raising its price target to $3 from $2, suggesting potential upside from the referenced $2.46 share price. Piper Sandler ratings
• Neutral Sentiment: The company announced CFO changes, but the provided report did not specify details or their expected financial impact. CFO changes announcement
• Negative Sentiment: Management narrowed 2026 revenue guidance to $155 million–$160 million, and an analyst account noted weaker gross margins. The company continues to burn substantial cash and is targeting cash-flow breakeven only in 2028, raising concerns about its financial runway. Revenue guidance and breakeven article Q3 guidance analysis
• Negative Sentiment: Barclays raised its price target to $2 from $1.25 but retained an underweight rating; the new target remains below the referenced share price. Barclays rating report

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.